Latest Insider Transactions at Eli Lilly & CO (LLY)
This section provides a real-time view of insider transactions for Eli Lilly & CO (LLY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ELI LILLY & Co to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ELI LILLY & Co's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2022
|
Anat Hakim EVP, GC & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,929
+39.07%
|
-
|
|
Feb 25
2022
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Open market or private sale
|
Direct |
1,660
-18.58%
|
$403,380
$243.84 P/Share
|
|
Feb 22
2022
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
41
+0.06%
|
$9,799
$239.13 P/Share
|
|
Feb 22
2022
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
53
+0.39%
|
$12,667
$239.13 P/Share
|
|
Feb 22
2022
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
40
+3.41%
|
$9,560
$239.13 P/Share
|
|
Feb 22
2022
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
41
+5.11%
|
$9,799
$239.13 P/Share
|
|
Feb 22
2022
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
47
+0.09%
|
$11,233
$239.13 P/Share
|
|
Feb 16
2022
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
2,186
-21.53%
|
$531,198
$243.84 P/Share
|
|
Feb 16
2022
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
5,461
+34.98%
|
-
|
|
Feb 16
2022
|
Ilya Yuffa EVP&Pres, LLY USA&Global Capab |
SELL
Open market or private sale
|
Direct |
1,000
-7.92%
|
$242,000
$242.58 P/Share
|
|
Feb 15
2022
|
Ilya Yuffa EVP&Pres, LLY USA&Global Capab |
SELL
Open market or private sale
|
Direct |
1,000
-7.34%
|
$237,000
$237.45 P/Share
|
|
Feb 09
2022
|
Anat Ashkenazi EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,752
+15.47%
|
$1,397,736
$243.27 P/Share
|
|
Feb 09
2022
|
Stephen F Fry SVP, HR & Diversity |
BUY
Grant, award, or other acquisition
|
Direct |
12,339
+7.48%
|
$2,998,377
$243.27 P/Share
|
|
Feb 09
2022
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,435
+20.87%
|
$1,320,705
$243.27 P/Share
|
|
Feb 09
2022
|
Patrik Jonsson EVP&Pres, CardMetHlth, LLY USA |
BUY
Grant, award, or other acquisition
|
Direct |
2,036
+5.86%
|
$494,748
$243.27 P/Share
|
|
Feb 09
2022
|
Michael B Mason EVP & Pres., Lilly Diabetes |
BUY
Grant, award, or other acquisition
|
Direct |
2,612
+8.67%
|
$634,716
$243.27 P/Share
|
|
Feb 09
2022
|
Johna Norton EVP, Global Quality |
BUY
Grant, award, or other acquisition
|
Direct |
3,294
+9.82%
|
$800,442
$243.27 P/Share
|
|
Feb 09
2022
|
Leigh Ann Pusey EVP, Corp. Affairs & Comm. |
BUY
Grant, award, or other acquisition
|
Direct |
5,309
+16.83%
|
$1,290,087
$243.27 P/Share
|
|
Feb 09
2022
|
David A Ricks President, Chair, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
68,004
+12.69%
|
$16,524,972
$243.27 P/Share
|
|
Feb 09
2022
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Grant, award, or other acquisition
|
Direct |
22,581
+22.33%
|
$5,487,183
$243.27 P/Share
|
|
Feb 09
2022
|
Alonzo Weems EVP, ERM & CECO |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+29.79%
|
$906,633
$243.27 P/Share
|
|
Feb 09
2022
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Grant, award, or other acquisition
|
Direct |
11,348
+18.39%
|
$2,757,564
$243.27 P/Share
|
|
Feb 09
2022
|
Ilya Yuffa EVP&Pres, LLY USA&Global Capab |
BUY
Grant, award, or other acquisition
|
Direct |
3,275
+19.38%
|
$795,825
$243.27 P/Share
|
|
Feb 09
2022
|
Donald A Zakrowski SVP, Finance, & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
2,947
+24.8%
|
$716,121
$243.27 P/Share
|
|
Feb 01
2022
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
25,170
-5.92%
|
$6,166,650
$245.39 P/Share
|
|
Feb 01
2022
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
56,205
+11.68%
|
-
|
|
Feb 01
2022
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
SELL
Payment of exercise price or tax liability
|
Direct |
8,437
-13.1%
|
$2,067,065
$245.39 P/Share
|
|
Feb 01
2022
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Exercise of conversion of derivative security
|
Direct |
18,735
+22.53%
|
-
|
|
Feb 01
2022
|
Stephen F Fry SVP, HR & Diversity |
SELL
Payment of exercise price or tax liability
|
Direct |
4,554
-3.14%
|
$1,115,730
$245.39 P/Share
|
|
Feb 01
2022
|
Stephen F Fry SVP, HR & Diversity |
BUY
Exercise of conversion of derivative security
|
Direct |
10,170
+6.56%
|
-
|
|
Feb 01
2022
|
Johna Norton EVP, Global Quality |
SELL
Payment of exercise price or tax liability
|
Direct |
1,194
-4.24%
|
$292,530
$245.39 P/Share
|
|
Feb 01
2022
|
Johna Norton EVP, Global Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
2,676
+8.68%
|
-
|
|
Feb 01
2022
|
Leigh Ann Pusey EVP, Corp. Affairs & Comm. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,010
-8.76%
|
$492,450
$245.39 P/Share
|
|
Feb 01
2022
|
Leigh Ann Pusey EVP, Corp. Affairs & Comm. |
BUY
Exercise of conversion of derivative security
|
Direct |
4,416
+16.14%
|
-
|
|
Feb 01
2022
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Payment of exercise price or tax liability
|
Direct |
4,204
-9.73%
|
$1,029,980
$245.39 P/Share
|
|
Feb 01
2022
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Exercise of conversion of derivative security
|
Direct |
9,368
+17.82%
|
-
|
|
Jan 18
2022
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
46
+0.09%
|
$11,362
$247.07 P/Share
|
|
Jan 18
2022
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
39
+3.45%
|
$9,633
$247.07 P/Share
|
|
Jan 18
2022
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
51
+0.38%
|
$12,597
$247.07 P/Share
|
|
Jan 18
2022
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
40
+5.26%
|
$9,880
$247.07 P/Share
|
|
Jan 18
2022
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
40
+0.06%
|
$9,880
$247.07 P/Share
|
|
Dec 30
2021
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
3,614
-0.0%
|
$1,008,306
$279.55 P/Share
|
|
Dec 27
2021
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
3,570
-0.0%
|
$996,030
$279.53 P/Share
|
|
Dec 20
2021
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
41
+0.08%
|
-
|
|
Dec 20
2021
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
37
+3.39%
|
$9,731
$263.48 P/Share
|
|
Dec 20
2021
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
8
+0.01%
|
$2,104
$263.48 P/Share
|
|
Dec 16
2021
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
177,616
-0.04%
|
$49,910,096
$281.39 P/Share
|
|
Dec 15
2021
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
205,000
-0.02%
|
$55,555,000
$271.49 P/Share
|
|
Nov 15
2021
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
677
+50.0%
|
$174,666
$258.43 P/Share
|
|
Nov 15
2021
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
685
+0.55%
|
$176,730
$258.43 P/Share
|